Interaction Checker

Interacciones de Coriogonadotropina alfa

Coriogonadotropina alfa (Ovidrel) tiene 60 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 37; moderadas: 23; leves: 0; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (37)

  • Acetazolamidainhibidor de la anhidrasa carbónicaGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Ácido etacrínicodiurético de asaGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Amiloridadiurético ahorrador de potasioGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Atenolol y clortalidonabetabloqueanteGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Benazepril e hidroclorotiazidainhibidor de la ECAGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Bisoprolol e hidroclorotiazidabetabloqueanteGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Bumetanidadiurético de asaGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Candesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Grave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Clorotiazidadiurético tiazídicoGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Clortalidonadiurético tiazídicoGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Enalapril e hidroclorotiazidainhibidor de la ECAGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Eplerenonaantagonista de la aldosteronaGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Espironolactonaantagonista de la aldosteronaGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Espironolactona e hidroclorotiazidaantagonista de la aldosteronaGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Fosinopril e hidroclorotiazidainhibidor de la ECAGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Furosemidadiurético de asaGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Hidroclorotiazidadiurético tiazídicoGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Indapamidadiurético tiazídicoGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Irbesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Grave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Levotiroxinahormona tiroideaGrave

    Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (etiqueta de Coriogonadotropina alfa, Contraindicaciones)

  • Levotiroxina y liotironinahormona tiroideaGrave

    Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (etiqueta de Coriogonadotropina alfa, Contraindicaciones)

  • Liotironinahormona tiroideaGrave

    Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (etiqueta de Coriogonadotropina alfa, Contraindicaciones)

  • Lisinopril e hidroclorotiazidainhibidor de la ECAGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Losartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Grave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Metimazolfármaco antitiroideoGrave

    Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (etiqueta de Coriogonadotropina alfa, Contraindicaciones)

  • Metolazonadiurético tiazídicoGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Metoprolol e hidroclorotiazidabetabloqueanteGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Olmesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Grave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Olmesartán, amlodipino e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Grave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Propiltiouracilofármaco antitiroideoGrave

    Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (etiqueta de Coriogonadotropina alfa, Contraindicaciones)

  • Quinapril e hidroclorotiazidainhibidor de la ECAGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Telmisartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Grave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Teriparatidahormona tiroideaGrave

    Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (etiqueta de Coriogonadotropina alfa, Contraindicaciones)

  • Torasemidadiurético de asaGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Triamterenodiurético ahorrador de potasioGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Triamtereno e hidroclorotiazidadiurético ahorrador de potasioGrave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Valsartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Grave

    Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etiqueta de Coriogonadotropina alfa, Advertencias)

Interacciones moderadas (23)

  • BicalutamidaandrógenoModerada

    PRECAUTIONS General Induction of androgen secretion by hCG may cause fluid retention. (etiqueta de Coriogonadotropina alfa, Precauciones)

  • DanazolandrógenoModerada

    PRECAUTIONS General Induction of androgen secretion by hCG may cause fluid retention. (etiqueta de Coriogonadotropina alfa, Precauciones)

  • Desogestrel y etinilestradiolanticonceptivo oralModerada

    Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Diacetato de etinodiol y etinilestradiolanticonceptivo oralModerada

    Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Drospirenona y etinilestradiolanticonceptivo oralModerada

    Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • EstradiolestrógenoModerada

    Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Estradiol y dienogestanticonceptivo oralModerada

    Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Estradiol y noretisteronaestrógenoModerada

    Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Estrógenos conjugadosestrógenoModerada

    Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Estrógenos conjugados y bazedoxifenoestrógenoModerada

    Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Estrógenos esterificados y metiltestosteronaestrógenoModerada

    Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Etonogestrel y etinilestradiolestrógenoModerada

    Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • FlutamidaandrógenoModerada

    PRECAUTIONS General Induction of androgen secretion by hCG may cause fluid retention. (etiqueta de Coriogonadotropina alfa, Precauciones)

  • FulvestrantestrógenoModerada

    Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Gonadotropina coriónicaModerada

    Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Levonorgestrel y etinilestradiolanticonceptivo oralModerada

    Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • MetiltestosteronaandrógenoModerada

    PRECAUTIONS General Induction of androgen secretion by hCG may cause fluid retention. (etiqueta de Coriogonadotropina alfa, Precauciones)

  • Norelgestromina y etinilestradiolestrógenoModerada

    Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Noretisterona y etinilestradiolanticonceptivo oralModerada

    Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Norgestimato y etinilestradiolanticonceptivo oralModerada

    Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • Norgestrel y etinilestradiolanticonceptivo oralModerada

    Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • ProgesteronaprogestágenoModerada

    The indices most generally used are as follows: A rise in basal body temperature Increase in serum progesterone and Menstruation following a shift in basal body temperature Urinary or serum luteinizing hormone (LH) rise When used in conjunction with the indices of progesterone production, sonographic visualization of the ovaries will assist in determining if… (etiqueta de Coriogonadotropina alfa, Precauciones)

  • TestosteronaandrógenoModerada

    PRECAUTIONS General Induction of androgen secretion by hCG may cause fluid retention. (etiqueta de Coriogonadotropina alfa, Precauciones)

Compruebe Coriogonadotropina alfa frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.